Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation
Peter J. Darlington(Concordia University), Marjorie A. Bowman(United States Department of Veterans Affairs), Dominique Gauchat(Université de Montréal), Rémi Cheynier(Sorbonne Université), Mark S. Freedman(University of Ottawa), Harold Atkins(University of Ottawa), Hania Kébir(University of Pennsylvania), Rafick‐Pierre Sékaly(University Hospitals of Cleveland), Denis Gaucher(Université de Montréal), Jean-Sébastien Doucet(Montreal Neurological Institute and Hospital), Jack P. Antel(Montreal Neurological Institute and Hospital), Douglas L. Arnold(McGill University), Alexandre Prat(Université de Montréal), Joumana Zeidan(Université de Montréal), Amit Bar‐Or(University of Pennsylvania), Tarik Touil(Montreal Neurological Institute and Hospital), Martin Duddy(Montreal Neurological Institute and Hospital), Rachel Corsini(McGill University Health Centre), Ho Jin Kim(National Cancer Center), Jacqueline Chen(Montreal Neurological Institute and Hospital), Nathalie Arbour(Centre Hospitalier de l’Université de Montréal), Farzaneh Jalili(Montreal Neurological Institute and Hospital)
Cited by 152
Related Papers
The Blood–Brain Barrier
|Cold Spring Harbor Perspectives in Biology|2015|3.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation
|Nature Medicine|2007|1.8k
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
|Nature Medicine|2009|1.7k